Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : Gets Europe OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/04/2019 | 07:14am EDT

By Colin Kellaher

Merck & Co. (MRK) on Wednesday said the European Commission approved the company's cancer drug Keytruda in combination with Pfizer Inlyta for the first-line treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer.

The Kenilworth, N.J., drug maker said the approval includes patients in all IMDC risk groups.

The European Medicines Agency's Committee for Medicinal Products for Human Use in July recommended EC approval of the combination, which received clearance from the U.S. Food and Drug Administration in April.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY -0.18% 82.61 Delayed Quote.8.11%
PFIZER -0.99% 36.91 Delayed Quote.-15.44%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09/13MERCK AND COMPANY : Ex-dividend day for
FA
09/10Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017..
DJ
09/10MERCK AND : - Pivotal New Data from 's Broad Oncology Portfolio at ESMO 2019 Con..
AQ
09/10MERCK : Announces First Nine “Safer Childbirth Cities” Committed to ..
BU
09/10MERCK AND : Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) ..
BU
09/09MERCK AND : Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 ..
BU
09/08BERGENBIO : Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcent..
AQ
09/05MERCK : to Present at the Morgan Stanley 17th Annual Global Healthcare Conferenc..
BU
09/04MERCK FOUNDATION : Launches Five-Year Initiative to Reduce Disparities in HIV Ca..
BU
09/04MERCK AND : Gets Europe OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma
DJ
More news
Financials (USD)
Sales 2019 45 855 M
EBIT 2019 15 626 M
Net income 2019 10 923 M
Debt 2019 19 506 M
Yield 2019 2,66%
P/E ratio 2019 19,9x
P/E ratio 2020 16,5x
EV / Sales2019 5,04x
EV / Sales2020 4,69x
Capitalization 212 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 96,67  $
Last Close Price 82,61  $
Spread / Highest target 27,1%
Spread / Average Target 17,0%
Spread / Lowest Target 7,74%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY8.11%211 513
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
PFIZER-15.44%204 151
NOVARTIS18.45%200 777
NOVO NORDISK AS14.89%118 168